ritonavir-话题@MedSci

[GetTopicListResponse(id=1793391, encodeId=f90d1e93391de, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=武汉金银谭医院的临床研究证实，lopinavir-ritonavir抗HIV组合可减轻新冠COVID-19患者症状, objectType=article, longId=191735, objectId=0487191e35a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0487191e35a3, replyNumber=0, likeNumber=48, createdTime=2021-01-03, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0487191e35a3, moduleTitle=武汉金银谭医院的临床研究证实，lopinavir-ritonavir抗HIV组合可减轻新冠COVID-19患者症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0487191e35a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793389, encodeId=61261e93389f8, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=J Viral Hepat：采用Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir和Ribavirin等药物治疗HBV和H, objectType=article, longId=129423, objectId=33a2129423ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a2129423ba, replyNumber=0, likeNumber=54, createdTime=2018-10-21, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a2129423ba, moduleTitle=J Viral Hepat：采用Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir和Ribavirin等药物治疗HBV和H, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33a2129423ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793390, encodeId=19571e93390f4, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究, objectType=article, longId=146130, objectId=8c0f14613063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0f14613063, replyNumber=0, likeNumber=54, createdTime=2018-10-26, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0f14613063, moduleTitle=Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c0f14613063)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ritonavir

2020-05-29

41514487@qq.com (审核中...)

前往app查看评论内容

#ritonavir#

武汉金银谭医院的临床研究证实，lopinavir-ritonavir抗HIV组合可减轻新冠COVID-19患者症状

2021-01-03

41514487@qq.com (审核中...)

前往app查看评论内容

#ritonavir#

J Viral Hepat：采用Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir和Ribavirin等药物治疗HBV和H

2018-10-21

41514487@qq.com (审核中...)

前往app查看评论内容

#ritonavir#

Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究

2018-10-26

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#ritonavir#

科室

工具

服务